FibroBiologics Secures European Patent for Fibroblast Conditioning Methods Covering Spinal Disc Regeneration

Cell therapy manufacturers and CDMOs scaling fibroblast-based platforms now face a more defined IP boundary in Europe: FibroBiologics, Inc. has received a grant from the European Patent Office for Patent No. 3568465, covering methods of conditioning fibroblasts with platelet rich plasma (PRP) and specific cytokines to enhance their regenerative, anti-inflammatory, and angiogenic activity prior to therapeutic use.

The granted claims are technically specific. Conditioning protocols must include PRP combined with FGF-alpha or FGF-beta, with additional coverage extending to cytokine combinations incorporating members of the TGF-beta family. Claims also address the conditioned fibroblasts themselves, sourced by biopsy and expanded in culture, derived from a defined list of tissue origins including skin, bone marrow, and adipose tissue, and their delivery in pharmaceutically acceptable carriers: sterile solutions, hydrogels, implantable cell matrices, and devices. For process development teams, the breadth of delivery-format claims is the detail that warrants closest review.

Two clinical indications anchor the patent's applied claims: angiogenesis-dependent tissue repair and intervertebral disc regeneration. The latter is directly tied to FibroBiologics' active disc degeneration clinical pathway. The patent describes the biological rationale in detail, degenerating discs lose proteoglycans and water content, undergo collagen compositional shifts, and trigger inflammatory cascades, framing the conditioning step as a means of priming fibroblasts to restore matrix before implantation, rather than managing symptoms post-degeneration.

For regulatory affairs leads, the European grant extends IP protection that complements the company's existing portfolio of 270-plus issued and pending patents across multiple chronic disease areas. Manufacturers evaluating fibroblast-based platform licensing or co-development arrangements in EU markets will need to map their own conditioning workflows against the granted claims, particularly where PRP and cytokine pre-treatment steps are part of the upstream process.

The conditioning patent's scope, spanning cell sourcing, ex vivo preparation, and final formulation format, positions it as a process-level asset rather than a composition-of-matter claim alone, a distinction that carries weight for any CDMO or sponsor assessing freedom-to-operate in the European cell therapy manufacturing space.

The next measurable checkpoint for this program is progression through FibroBiologics' disc degeneration clinical pathway, where the conditioned fibroblast approach described in the patent will face translational validation against the regenerative endpoints the claims are built around.

Source: FibroBiologics, Inc. via PR Newswire, 29 September 2026.